Previous close | 1.5400 |
Open | 1.5020 |
Bid | 1.6880 x 20000 |
Ask | 1.5940 x 12500 |
Day's range | 1.5020 - 1.5980 |
52-week range | 1.2000 - 3.4000 |
Volume | |
Avg. volume | 76,687 |
Market cap | 59.648M |
Beta (5Y monthly) | 1.62 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.5400 |
Earnings date | 10 May 2024 - 14 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Oslo, Norway 3 May 2024 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 24 May 2024 at 10:00am (CEST). The notice and proposed resolutions to the annual general meeting are attached. The notice, including all appendices, will be made available at PCI Biotech's corporate website www.pcibiotech.com. For further information, please contact:Ronny Skuggedal, CEO/CFO, E-mail: rs@pcibiotech.noOffice: +47 67 11 54 00
Oslo (Norway), 14 February 2024 – PCI Biotech (OSE: PCIB), today announces its interim second half 2023 results. Please find enclosed the interim report and presentation. Highlights review OperationsThe use of fimaNAc in gene therapy manufacturing has since its inception in 2022 generated results supporting the notion of applying photochemical methods to increase yield and reduce impurities in bioprocessing, specifically viral vector manufacturing. The most recently reported 2023 milestone was i
Oslo, Norway, 12 February 2024 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's second half 2023 interim report on Wednesday 14 February 2024, 08:30am – 09:30am CET (local time). The presentation will be held as a live webcast and can be accessed through www.pcibiotech.com. The presentation will be held in Norwegian. There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console. The interim rep